Clinical trials: Physiological Conditions
Bradyarrhythmia
Clinical Outcome of Pacemaker paTIents According to Pacing Modality and Primary INDications
The study objective is to collect mid-term clinical outcome in a group of patients implanted with permanent pacemaker (PM) according to real-life clinical practice in a multicenter and international environment.
- Trial name
- OPTI-MIND (NCT00976482)
- Where
- Germany
- Volunteers
- 1,745 people
- Sponsor
- Boston Scientific Corporation
Pain, Postoperative, Postoperative Nausea and Vomiting
Efficacy Safety Score in Postoperative Management
The primary aim of this project is to determine whether postoperative patients may benefit from the Efficacy Safety Score (ESS) as a tool for postoperative clinical decision support, with a special focus on the first 24 hours…
- Trial name
- NCT03438578
- Testing
- Efficacy Safety Score monitoring
- Where
- Norway
- Volunteers
- 200 people
- Sponsor
- St. Olavs Hospital
Sedation, Critical Illness
Musical Intervention and Physiological Stress and Inflammatory Biomarkers in Mechanically Ventilated ICU Patients
This randomized clinical trial evaluates the effects of a musical intervention on hormonal and inflammatory biomarkers in sedated adult patients undergoing invasive mechanical ventilation in an intensive care unit.
- Conditions
- Sedation, Critical Illness, Respiration, Artificial, Inflammation
- Trial name
- NCT06120660
- Testing
- Music Therapy
- Where
- Spain
- Volunteers
- 110 people
- Sponsor
- University of Oviedo
Proctitis, Proctosigmoiditis
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
The purpose of this study is to establish the efficacy profile of rectally administered budesonide foam, as compared to an equivalent volume of rectally administered placebo foam over the same dosing schedule, in participants who…
- Trial name
- NCT01008423
- Testing
- Budesonide
- Where
- 62 sites in United States
- Volunteers
- 281 people
- Sponsor
- Bausch Health Americas, Inc.
Bradycardia
Effectiveness of Pacemaker With Closed Loop Stimulation Compared to Pacemakers With and Without Standard Rate Response
This is a randomized, prospective, single-blinded, multi-center study involving approximately 1500 patients at 100 centers. The purpose of this study is to demonstrate the effectiveness of Closed Loop Stimulation (CLS) rate…
- Trial name
- CLEAR (NCT00355797)
- Testing
- Closed Loop Stimulation (CLS), Standard Rate Adaptive (R) Technology, Non-rate adaptive (DDD) pacing
- Where
- 99 sites in United States
- Volunteers
- 1,491 people
- Sponsor
- Biotronik, Inc.
Vasomotor Symptoms (VMS)
Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen
Open-label, two dose study of Q-122, over a 4 week treatment period to explore the effects of Q-122 in a population of women with a history of breast cancer taking an aromatase inhibitor or tamoxifen.
- Trial name
- NCT04080297
- Testing
- oral capsule of Q-122
- Volunteers
- 21 people
- Sponsor
- Que Oncology
Anemia of End Stage Renal Disease
TARGTEPO Treatment for Anemia in PD US Trial
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
- Trial name
- NCT02468414
- Testing
- MDGN201 TARGTEPO
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Fear Pain
Human Behaviors Related to the Expectation of Pain
The conditioned expectation of pain is an important aspect of pain-related disability produced by environments and stimuli associated with a painful injury on the job, although the neuroscience of this expectation is unclear.
- Trial name
- NCT03739645
- Testing
- Skin conductance levels and slopes over time in conditioned fear as metrics.as metrics for anxiety
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Diabetic Macular Edema
Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema
The purpose of this clinical trial is to compare safety, tolerability, efficacy, and durability of two dose levels of suprachoroidal sustained-release OXU-001 (dexamethasone microspheres; DEXAspheres®) using the Oxulumis®…
- Trial name
- OXEYE (NCT05697809)
- Testing
- OXU-001, Semi-automated suprachoroidal illuminated microcatheter, Ozurdex® Ophthalmic Intravitreal Implant
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 3 people
- Sponsor
- Oxular Limited
Sleep Initiation and Maintenance Disorders, Anxiety
HIRREM Developmental Study
The purpose of this study is to explore the functional and physiological effects associated with the use of High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM), as supplemental care, for symptoms of…
- Conditions
- Sleep Initiation and Maintenance Disorders, Anxiety, Post-Traumatic Stress Disorder, Hot Flashes
- Trial name
- NCT02709369
- Testing
- HIRREM
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Wake Forest University Health Sciences
Brain Edema, Stroke, Acute
Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
The primary objective of Part 1 of the study is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric…
- Trial name
- CHARM (NCT02864953)
- Testing
- BIIB093
- Where
- 250 sites in United States, Australia and 22 more
- Volunteers
- 535 people
- Sponsor
- Remedy Pharmaceuticals, Inc.
Circulatory Shock, Cardiovascular Shock
Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock.
This is an open-label, single center, trial that will enroll up to 25 participants with circulatory shock after cardiac surgery.
- Trial name
- NCT05102734
- Testing
- Nitroglycerin Topical Product
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Pennsylvania
Anterior Ischemic Optic Neuropathy
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The primary objective of this study is to determine whether the use of PDE5 inhibitors (vardenafil, sildenafil, or tadalafil) increases the risk for the development of NAION.
- Trial name
- NCT00867815
- Testing
- Diagnostic procedures
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Bayer
Postoperative Pain
Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery
The primary purpose of this study is to determine if CR845 is effective in treating the pain associated with a laparoscopic hysterectomy.
- Trial name
- NCT01361568
- Testing
- CR845
- Where
- 18 sites in United States
- Volunteers
- 203 people
- Sponsor
- Cara Therapeutics, Inc.
Endometriosis
A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement…
- Trial name
- NCT03986944
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 112 sites in United States, Canada and 1 more
- Volunteers
- 85 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
End Stage Renal Disease
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
The purpose of this study is to compare the clinical safety and efficacy of SFP in sparing the need for erythropoiesis stimulating agents (ESAs) required to maintain hemoglobin (hgb) levels in chronic hemodialysis subjects who…
- Trial name
- PRIME (NCT01286012)
- Testing
- Soluble Ferric Pyrophosphate in liquid bicarbonate, Erythrocyte Stimulating Agent (ESA), Intravenous (IV) Iron
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 108 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Alzheimer's Disease, Vascular Dementia
Effect of Insulin Sensitizer Metformin on AD Biomarkers
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive loss of memory and other cognitive functions.
- Conditions
- Alzheimer's Disease, Vascular Dementia, Dementia, Memory Impairment
- Trial name
- NCT01965756
- Testing
- Metformin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Tinnitus
Regulating Homeostatic Plasticity and the Physiological Response to rTMS
This device-study includes a pilot, physiological investigation of normal human subjects. The aim is to determine how existing non-invasive neuromodulation devices affect brain circuitry as measured by EEG recording.
- Trial name
- NCT03309696
- Testing
- active tDCS and active rTMS
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Spinal Cord Injury, Acute Spinal Cord Injury
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
The overall objective of this study is to define an effective therapeutic approach, using currently available medication, to prevent or mitigate the loss of bone mass and bone strength that occurs after acute spinal cord injury.
- Conditions
- Spinal Cord Injury, Acute Spinal Cord Injury, Bone Loss, Osteoporosis
- Trial name
- NCT02325414
- Testing
- Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Endometriosis
Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement…
- Trial name
- NCT03992846
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 71 sites in United States, Austria and 8 more
- Volunteers
- 486 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.